Epoch Investment Partners Inc. Buys 39,526 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Epoch Investment Partners Inc. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 197,266 shares of the biopharmaceutical company’s stock after acquiring an additional 39,526 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Regeneron Pharmaceuticals were worth $140,518,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in REGN. Virtu Financial LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $6,364,000. Morse Asset Management Inc grew its holdings in shares of Regeneron Pharmaceuticals by 0.9% during the third quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company’s stock valued at $5,053,000 after buying an additional 43 shares during the last quarter. Anchor Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 212.0% during the third quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company’s stock worth $902,000 after acquiring an additional 583 shares in the last quarter. Sculati Wealth Management LLC increased its position in shares of Regeneron Pharmaceuticals by 1.9% during the third quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company’s stock worth $1,970,000 after acquiring an additional 38 shares in the last quarter. Finally, Pine Valley Investments Ltd Liability Co raised its holdings in shares of Regeneron Pharmaceuticals by 19.0% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company’s stock worth $5,575,000 after acquiring an additional 848 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $563.16 on Friday. The firm has a market capitalization of $61.57 billion, a PE ratio of 14.71, a P/E/G ratio of 2.34 and a beta of 0.44. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $645.94 and a two-hundred day moving average price of $740.52. Regeneron Pharmaceuticals, Inc. has a twelve month low of $525.99 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the firm earned $11.86 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.63%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Wall Street Analyst Weigh In

A number of analysts have commented on REGN shares. Canaccord Genuity Group decreased their price objective on Regeneron Pharmaceuticals from $170.00 to $150.00 and set a “hold” rating for the company in a report on Thursday. TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. The Goldman Sachs Group cut their price objective on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Piper Sandler lowered their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. Finally, Sanford C. Bernstein cut their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $963.56.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.